{"id":"https://openalex.org/W2986154089","doi":"https://doi.org/10.1182/blood-2019-124297","title":"A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis","display_name":"A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2986154089","doi":"https://doi.org/10.1182/blood-2019-124297","mag":"2986154089"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-124297","doi":"https://doi.org/10.1182/blood-2019-124297","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-124297","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102788725","display_name":"Wojciech J. Jurczak","orcid":"https://orcid.org/0000-0003-1879-8084","observed_orcids":["https://orcid.org/0000-0003-1879-8084"]},"institutions":[{"id":"https://openalex.org/I126596746","display_name":"Jagiellonian University","ror":"https://ror.org/03bqmcz70","country_code":"PL","type":"education","lineage":["https://openalex.org/I126596746"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Wojciech Jurczak","raw_affiliation_strings":["Department of Hematology, Jagiellonian University Medical College, Krak\u00f3w, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Jagiellonian University Medical College, Krak\u00f3w, Poland","institution_ids":["https://openalex.org/I126596746"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091882595","display_name":"Pier Luigi Zinzani","orcid":"https://orcid.org/0000-0002-2112-2651","observed_orcids":["https://orcid.org/0000-0002-2112-2651"]},"institutions":[{"id":"https://openalex.org/I4210117483","display_name":"Istituto di Ematologia di Bologna","ror":"https://ror.org/01mze9517","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210117483"]},{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Pier Luigi Zinzani","raw_affiliation_strings":["University of Bologna, Istituto Di Ematologia, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Bologna, Istituto Di Ematologia, Bologna, Italy","institution_ids":["https://openalex.org/I4210117483","https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011863718","display_name":"Georg He\u00df","orcid":"https://orcid.org/0000-0002-9282-5688","observed_orcids":["https://orcid.org/0000-0002-9282-5688"]},"institutions":[{"id":"https://openalex.org/I197323543","display_name":"Johannes Gutenberg University Mainz","ror":"https://ror.org/023b0x485","country_code":"DE","type":"education","lineage":["https://openalex.org/I197323543"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Georg Hess","raw_affiliation_strings":["Department of Hematology, Medical Oncology and Pneumology, Johannes Gutenberg University of Mainz, Mainz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Medical Oncology and Pneumology, Johannes Gutenberg University of Mainz, Mainz, Germany","institution_ids":["https://openalex.org/I197323543"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041745367","display_name":"Gianluca Ga\u00efdano","orcid":"https://orcid.org/0000-0002-4681-0151","observed_orcids":["https://orcid.org/0000-0002-4681-0151"]},"institutions":[{"id":"https://openalex.org/I123338534","display_name":"Universit\u00e0 degli Studi del Piemonte Orientale \u201cAmedeo Avogadro\u201d","ror":"https://ror.org/04387x656","country_code":"IT","type":"education","lineage":["https://openalex.org/I123338534"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Gianluca Gaidano","raw_affiliation_strings":["Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, Novara, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Department of Translational Medicine, Universit\u00e0 del Piemonte Orientale, Novara, Italy","institution_ids":["https://openalex.org/I123338534"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085499011","display_name":"Mariano Provencio","orcid":"https://orcid.org/0000-0001-9053-9197","observed_orcids":["https://orcid.org/0000-0001-9053-9197"]},"institutions":[{"id":"https://openalex.org/I4210105637","display_name":"Hospital Universitario Puerta de Hierro Majadahonda","ror":"https://ror.org/01e57nb43","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210105637","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I63634437","display_name":"Universidad Aut\u00f3noma de Madrid","ror":"https://ror.org/01cby8j38","country_code":"ES","type":"education","lineage":["https://openalex.org/I63634437"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Mariano Provencio","raw_affiliation_strings":["Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Aut\u00f3noma de Madrid, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Aut\u00f3noma de Madrid, Madrid, Spain","institution_ids":["https://openalex.org/I4210105637","https://openalex.org/I63634437"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101865823","display_name":"Zsolt Nagy","orcid":"https://orcid.org/0000-0001-9756-5427","observed_orcids":["https://orcid.org/0000-0001-9756-5427"]},"institutions":[{"id":"https://openalex.org/I101202996","display_name":"Semmelweis University","ror":"https://ror.org/01g9ty582","country_code":"HU","type":"education","lineage":["https://openalex.org/I101202996"]}],"countries":["HU"],"is_corresponding":false,"raw_author_name":"Zsolt Nagy","raw_affiliation_strings":["1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary","institution_ids":["https://openalex.org/I101202996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087571749","display_name":"Tadeusz Robak","orcid":"https://orcid.org/0000-0002-3411-6357","observed_orcids":["https://orcid.org/0000-0002-3411-6357"]},"institutions":[{"id":"https://openalex.org/I4210122071","display_name":"Medical University of Lodz","ror":"https://ror.org/02t4ekc95","country_code":"PL","type":"education","lineage":["https://openalex.org/I4210122071"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Tadeusz Robak","raw_affiliation_strings":["Department of Hematology, Medical University of Lodz, Lodz, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Medical University of Lodz, Lodz, Poland","institution_ids":["https://openalex.org/I4210122071"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024389256","display_name":"Kami J. Maddocks","orcid":"https://orcid.org/0000-0001-8519-8404","observed_orcids":["https://orcid.org/0000-0001-8519-8404"]},"institutions":[{"id":"https://openalex.org/I2802841970","display_name":"The Ohio State University Wexner Medical Center","ror":"https://ror.org/00c01js51","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802841970"]},{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kami J. Maddocks","raw_affiliation_strings":["Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH","institution_ids":["https://openalex.org/I2802841970","https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022277766","display_name":"Christian Buske","orcid":"https://orcid.org/0000-0002-9782-9012","observed_orcids":["https://orcid.org/0000-0002-9782-9012"]},"institutions":[{"id":"https://openalex.org/I196349391","display_name":"Universit\u00e4t Ulm","ror":"https://ror.org/032000t02","country_code":"DE","type":"education","lineage":["https://openalex.org/I196349391"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Christian Buske","raw_affiliation_strings":["Institute for Experimental Cancer Research, Comprehensive Cancer Center Ulm, Ulm, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute for Experimental Cancer Research, Comprehensive Cancer Center Ulm, Ulm, Germany","institution_ids":["https://openalex.org/I196349391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007316044","display_name":"Sumeet Ambarkhane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Sumeet Ambarkhane","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109081750","display_name":"Wolfram Brugger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Wolfram Brugger","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050782079","display_name":"Maren Dirnberger\u2010Hertweck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Maren Dirnberger-Hertweck","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046261996","display_name":"Sascha Tillmanns","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Sascha Tillmanns","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007901103","display_name":"Johannes Weirather","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Johannes Weirather","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056946123","display_name":"Kristie A. Blum","orcid":"https://orcid.org/0000-0001-7363-9794","observed_orcids":["https://orcid.org/0000-0001-7363-9794","https://orcid.org/0000-0003-4229-2569"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristie Blum","raw_affiliation_strings":["Department of Hematology and Medical Oncology, Emory University, Winship Cancer Institute, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Medical Oncology, Emory University, Winship Cancer Institute, Atlanta, GA","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I4390039307"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":25,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"4078","last_page":"4078"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9707000255584717,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9707000255584717,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.017999999225139618,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tafasitamab","display_name":"tafasitamab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/anti-cd19-monoclonal-antibody","display_name":"anti-CD19 monoclonal antibody","score":0.9700000286102295},{"id":"https://openalex.org/keywords/fc-enhanced-antibody","display_name":"Fc-enhanced antibody","score":0.8349999785423279},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9789999723434448},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.9210000038146973},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9879999756813049},{"id":"https://openalex.org/keywords/indolent-non-hodgkin-lymphoma","display_name":"indolent non-Hodgkin lymphoma","score":0.8809999823570251},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.7760000228881836},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7400000095367432},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8349999785423279},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.5809999704360962},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.7110000252723694},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8489999771118164},{"id":"https://openalex.org/keywords/rituximab-refractory-disease","display_name":"rituximab-refractory disease","score":0.7919999957084656},{"id":"https://openalex.org/keywords/cd19","display_name":"CD19","score":0.421999990940094}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8785299062728882},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6461381912231445},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5848643183708191},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.581277072429657},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5264133810997009},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5130028128623962},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4840342402458191},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4681409001350403},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.466849148273468},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43530458211898804},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.42631179094314575},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37826552987098694},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3663915991783142},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.26752251386642456},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-124297","doi":"https://doi.org/10.1182/blood-2019-124297","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-124297","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2792232222","https://openalex.org/W2602241331","https://openalex.org/W2521775567","https://openalex.org/W7125378031","https://openalex.org/W3095291572","https://openalex.org/W2600991767","https://openalex.org/W2983147839","https://openalex.org/W2988395771","https://openalex.org/W3176363517","https://openalex.org/W3187785560"],"abstract_inverted_index":{"Background:":[0],"CD19":[1],"is":[2,26,36,240],"broadly":[3],"and":[4,11,62,150,154,159,187,260,287,305,314,325,329,426,443,473,482,851,860,869,879,889,900,911,920],"homogeneously":[5],"expressed":[6],"across":[7],"different":[8,232],"B-cell":[9,20,73],"malignancies":[10],"represents":[12],"an":[13,27,497,517,546,559,579,594,608,624,638,652,666,679,692,704,717,730,743,757,817,833,927,938,949,960,971,1033,1047,1066],"attractive":[14],"target":[15],"antigen":[16],"in":[17,43,230,242,247,285,290,312,338,399,411,470,477],"patients":[18,45,246,270,374,400,430,478],"with":[19,46,170,197,346,373,401,479],"non-Hodgkin's":[21],"lymphoma":[22,74,79,83],"(NHL).":[23],"Tafasitamab":[24,395,465],"(MOR208)":[25],"Fc-enhanced,":[28],"humanized,":[29],"anti-CD19":[30],"monoclonal":[31],"antibody.":[32],"This":[33],"ongoing":[34,198,259],"study":[35,65],"investigating":[37],"the":[38,104,120,141,157,192,205,231,266,456],"single":[39],"agent":[40],"antitumor":[41],"activity":[42],"adult":[44],"relapsed":[47],"or":[48,86,219,367,390,502,522,551,564,584,599,613,629,643,657,671,684,697,709,722,735,748,762,822,838,932,943,954,965,976,1038,1052,1071],"refractory":[49],"(r/r)":[50],"NHL":[51,69,89,484],"who":[52,375],"had":[53,359,376],"received":[54,164,210],"at":[55,199,204,234,265,320,357,380],"least":[56,200],"one":[57],"prior":[58,96],"rituximab-containing":[59],"therapy.":[60],"Patients":[61,163,196,345],"Methods:":[63],"The":[64,92,108,224,279,294,317,413],"enrolled":[66],"92":[67],"r/r":[68,402],"patients:":[70],"diffuse":[71],"large":[72],"(DLBCL;":[75],"n=35),":[76],"mantle":[77],"cell":[78,353],"(MCL;":[80],"n=12),":[81],"follicular":[82],"(FL;":[84],"n=34),":[85],"other":[87,256],"indolent":[88,483],"(iNHL;":[90],"n=11).":[91],"median":[93,280,295,361,384],"number":[94],"of":[95,144,161,173,178,207,363,386,450,500,520,549,562,582,597,611,627,641,655,669,682,695,707,720,733,746,760,820,836,930,941,952,963,974,1036,1050,1069],"systemic":[97],"therapies":[98],"was":[99,112,189,282,297,323,336,396,447,474],"three":[100,167,194],"(range":[101],"1-15)":[102],"for":[103,191,274,327],"entire":[105],"patient":[106],"population.":[107],"primary":[109],"efficacy":[110],"endpoint":[111],"investigator-assessed":[113,225],"overall":[114],"response":[115,145,227],"rate":[116,319],"(ORR)":[117],"based":[118],"on":[119,262,272,496,516,545,558,578,593,607,623,637,651,665,678,691,703,716,729,742,756,816,832,926,937,948,959,970,1032,1046,1065],"revised":[121],"International":[122],"Working":[123],"Group":[124],"Response":[125],"Criteria":[126],"(Cheson":[127],"et":[128,130],"al.,":[129],"al.":[131],"J":[132],"Clin":[133],"Oncol":[134],"2007).":[135],"Secondary":[136],"objectives":[137],"were":[138,258,271,409,419],"to":[139,148,155,166],"evaluate":[140],"time-to-response,":[142],"duration":[143],"(DoR),":[146],"time":[147],"progression":[149,468],"progression-free":[151],"survival":[152],"(PFS),":[153],"establish":[156],"safety":[158],"tolerability":[160],"tafasitamab.":[162,179],"up":[165],"28-day":[168],"cycles":[169],"weekly":[171],"infusions":[172],"12":[174,321],"mg/kg":[175],"body":[176],"weight":[177],"Premedication,":[180],"including":[181],"antipyretics,":[182],"histamine":[183],"H1":[184],"receptor":[185],"blockers":[186],"glucocorticosteroids,":[188],"administered":[190],"first":[193],"infusions.":[195],"partial":[201],"remission":[202,249],"(PR)":[203],"end":[206],"Cycle":[208],"3":[209],"further":[211],"tafasitamab":[212,263],"treatment":[213,264,273],"until":[214,467],"disease":[215],"progression,":[216],"either":[217],"monthly":[218],"every":[220],"second":[221],"week.":[222],"Results:":[223],"best":[226],"(intent-to-treat":[228],"analysis)":[229],"subgroups":[233],"cut-off":[235,267],"date":[236],"(28":[237],"Sep":[238],"2018)":[239],"shown":[241],"Table":[243],"1.":[244],"Five":[245],"complete":[248],"(CR)":[250],"(one":[251],"DLBCL,":[252],"two":[253,255],"FL,":[254,315,330],"iNHL)":[257],"still":[261],"date.":[268],"These":[269],"more":[275],"than":[276],"4":[277],"years.":[278],"DoR":[281],"20.1":[283],"months":[284,289,307,322,365,369,388,392],"DLBCL":[286,313,328],"24":[288],"FL":[291],"(Table":[292,332],"2).":[293,333],"PFS":[296,318,335,362,385],"2.7":[298],"(95%":[299,308],"confidence":[300],"interval":[301],"[CI]":[302],"2.1-13.2":[303],"months)":[304,311],"6.6":[306],"CI":[309],"5.3-20.5":[310],"respectively.":[316,394],"34.3%":[324],"39.2%":[326],"respectively":[331],"Similar":[334],"observed":[337],"rituximab-refractory":[339],"as":[340,342,371],"well":[341,397,475],"non-refractory":[343],"patients.":[344],"a":[347,360,383],"peripheral":[348],"blood":[349],"natural":[350],"killer":[351],"(NK)":[352],"count":[354],">100":[355],"cells/\u00b5L":[356,379],"baseline":[358,381],"4.2":[364],"(DLBCL)":[366,389],"8.8":[368],"(FL/iNHL),":[370,393],"compared":[372],"<100":[377],"NK":[378],"showing":[382],"2.1":[387],"3.2":[391],"tolerated":[398,476],"NHL.":[403],"Most":[404],"treatment-emergent":[405],"adverse":[406,434],"events":[407],"(TEAEs)":[408],"mild":[410],"nature.":[412],"most":[414],"common":[415],"grade":[416,451],"\u22653":[417,452],"TEAEs":[418],"neutropenia":[420],"(9.8%),":[421],"thrombocytopenia":[422],"(4.3%),":[423],"anemia":[424],"(3.3%)":[425],"pneumonia":[427],"(3.3%).":[428],"Four":[429],"(4.3%)":[431],"experienced":[432],"serious":[433],"reactions":[435],"(febrile":[436],"neutropenia,":[437],"genital":[438],"herpes":[439],"zoster,":[440],"infusion-related":[441],"reaction":[442],"myelodysplastic":[444],"syndrome).":[445],"There":[446],"no":[448,460],"evidence":[449],"late":[453],"toxicity":[454],"during":[455],"long-term":[457],"follow-up":[458],"period;":[459],"treatment-related":[461],"deaths":[462],"occurred.":[463],"Conclusion:":[464],"monotherapy":[466],"resulted":[469],"durable":[471],"responses":[472],"both":[480],"aggressive":[481],"subtypes.":[485],"Disclosures":[486],"Jurczak:":[487],"Celgene:":[488,714,778,1063],"Research":[489,492,505,509,512,525,529,532,535,538,541,554,567,570,573,785,794,800,806,891,902,981,985,993,997,1000,1008,1020,1024,1028,1042,1055,1058,1061,1075,1078,1082,1088],"Funding;":[490,493,506,510,513,526,530,533,536,539,542,555,568,571,786,795,801,807,982,986,994,998,1001,1009,1021,1025,1043,1056,1059,1062,1076,1079],"Bayer:":[491,1077],"AstraZeneca:":[494,864,1106],"Membership":[495,515,544,557,577,592,606,622,636,650,664,677,690,702,715,728,741,755,815,831,925,936,947,958,969,1031,1045,1064],"entity's":[498,518,547,560,580,595,609,625,639,653,667,680,693,705,718,731,744,758,818,834,928,939,950,961,972,1034,1048,1067],"Board":[499,519,548,561,581,596,610,626,640,654,668,681,694,706,719,732,745,759,819,835,929,940,951,962,973,1035,1049,1068],"Directors":[501,521,550,563,583,598,612,628,642,656,670,683,696,708,721,734,747,761,821,837,931,942,953,964,975,1037,1051,1070],"advisory":[503,523,552,565,585,600,614,630,644,658,672,685,698,710,723,736,749,763,823,839,933,944,955,966,977,1039,1053,1072],"committees,":[504,524,553,566,586,601,615,631,645,659,673,686,711,724,737,750,764,824,840,1054],"TG":[507,767],"Therapeutics:":[508,768],"Servier:":[511,676],"Sandoz:":[514,689],"Novo":[527],"Nordisk:":[528],"Roche:":[531,740,787,895,968,1015,1080],"MorphoSys:":[534,811],"Celtrion:":[537],"Gilead:":[540,634,995],"Loxo:":[543],"Janssen:":[556,830,957,1002,1086],"Takeda:":[569,935,1022],"Incyte:":[572],"Funding.":[574,1029],"Zinzani:Verastem:":[575],"Consultancy,":[576,590,605,773,779,788,803,809,812,828,844,847,856,865,875,885,896,907,916,984,988,996,1003,1011,1016,1023],"Speakers":[587,602,616,632,646,660,674,687,712,725,738,751,765,770,825,841,853,862,871,881,893,904,913,922,1084,1090,1096,1100],"Bureau;":[588,603,617,633,647,661,675,688,713,726,739,752,766,826,842,854,863,872,882,894,905,914,1085,1091,1097],"MSD:":[589,915],"Honoraria,":[591,621,635,649,663,769,774,781,790,805,989,1004,1027,1081,1087,1095,1099],"Eusapharma:":[604],"Sanofi:":[618],"Consultancy;":[619],"Celltrion:":[620,1094],"Janssen-Cilag:":[648],"BMS:":[662,906,1041],"committees;":[699,934,945,956,967,1040],"Immune":[700],"Design:":[701],"Portola:":[727],"Kyowa":[753],"Kirin:":[754],"Bureau.":[771,923,1101],"Hess:Janssen:":[772],"Other:":[775,782,791,797,848,857,866,876,886,897,908,917,990,1005,1012,1017],"personal":[776,783,792,798],"fees;":[777],"Employment,":[780,789,804],"fees,":[784,793,799],"Pfizer:":[796,1092],"CTI:":[802],"Novartis:":[808,855,1060],"Honoraria;":[810,829,1093],"Honoraria.":[813,845],"Gaidano:AbbVie:":[814],"Astra-Zeneca:":[827],"Sunesys:":[843],"Provencio:Takeda:":[846],"Travel,":[849,858,867,877,887,898,909,918],"accommodation":[850,859,868,878,888,899,910,919],"expenses,":[852,861,870,880,890,901,912,921],"Pierre":[873],"Fabre:":[874],"Boehringer":[883],"Ingelheim:":[884],"Funding,":[892,903,1083,1089],"Nagy:Novartis:":[924],"Abbvie:":[946,987],"committees.":[978,1073],"Robak:Morphosys":[979],"AG:":[980,1112],"BeiGene:":[983],"Travel":[991,1006,1013,1018],"grant,":[992,1007,1019],"Acerta:":[999],"Amgen:":[1010],"grant;":[1014],"UCB:":[1026],"Maddocks:Teva:":[1030],"Pharmacyclics:":[1044],"Merck:":[1057],"Buske:Amgen:":[1074],"Hexal:":[1098],"Ambarkhane:MorphoSys:":[1102],"Employment.":[1103,1110,1113,1115],"Brugger:MorphoSys:":[1104],"Employment;":[1105],"Equity":[1107],"Ownership.":[1108],"Dirnberger-Hertweck:MorphoSys:":[1109],"Tillmanns:MorphoSys":[1111],"Weirather:MorphoSys:":[1114]},"counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-11-22T00:00:00"}